 |
 |
> Subject: Re: Sinemet > From: Schaaf Angus / Meadow Creek Ranch <[log in to unmask]> > Date: Wed, 11 Jul 2001 00:11:25 -0600 All well and good, but studies like this just happen to omit the other things like the dystonia, dyskinesia, etc. that seem to crop up after a while ....... Rob ----- Original Message ----- From: "ervinmccarthy" <[log in to unmask]> To: <[log in to unmask]> Sent: Tuesday, July 10, 2001 7:39 PM Subject: Sinemet > Subject: Chronic LD not toxic, may promote neural recovery > Date: 1/19/99 > > Chronic levodopa is not toxic for remaining dopamine neurons, but instead > promotes their recovery, in rats with moderate nigrostriatal lesions > > MG Murer, G Dziewczapolski, LB Menalled, MC Garcia, Y Agid, O Gershanik, R > Raisman-Vozari > > Annals of Neurology, 1998, Vol 43, Iss 5, pp 561-575 > > Six months of oral l-dopa caused no excess loss of dopaminergic neurons > versus untreated controls, and may have promoted recovery of surviving > neurons, according to this study on OHDA-lesioned rats. Rats were > unilaterally injected with either saline or one of two quantities of OHDA > (to produce moderate vs. severe lesions). Members of each group were > randomly assigned to receive either vehicle or oral l-dopa. Neuronal > survival was quantified by immunoautoradiography of tyrosine hydroxylase, > vesicular monoamine transporter, and dopamine transporter. > > Results showed: > a) L-dopa treatment caused no loss of dopaminergic neurons in either > sham-lesioned or OHDA-lesioned rats compared to sham-lesioned, > non-treated controls > b) L-dopa treatment caused no reduction in terminal axonal arborization > c) In the moderately lesioned group, treated rats showed, "in the > denervated regions of the striatum, significantly higher levels of the > three dopaminergic markers than their corresponding vehicle-treated > control group, and also an increased density of TH-immunoreactive > fibers." > > The authors suggest the recovery is likely to be due to axonal sprouting of > surviving dopaminergic neurons. They also note that their study provided no > evidence of accompanying functional recovery in this subgroup. In discussing > the relevance of these findings to human PD > patients, they state "our results cannot be considered as definitive > evidence of an absence of toxicity of chronic levodopa in PD patients" but > note that other recent findings support the absence of l-dopa toxicity as > well. > > An editorial by Stanley Fahn accompanies the article. > > > -------------------------------------------------------------------------- -- > ---- > Copyright 2000 WE MOVE > Editor: Richard Robinson ([log in to unmask]) > This service is provided free of charge to the Internet community, courtesy > of WEMOVE.org. This document may be freely redistributed by email only in > its unedited form. We encourage you to share it with your colleagues. > > E-MOVE archives, plus information on subscribing, are available at > http://www.wemove.org/em_intro.html. To unsubscribe, send an e-mail to > [log in to unmask], with "unsubscribe e-move" in the message body. > > E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for > Movement Disorders) > 204 West 84th Street > New York, NY 10024 > > > TEL 800-437-MOV2 > TEL 212-241-8567 > FAX 212-987-7363 > http://www.wemove.org > > [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn